|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:awards
|
gptkb:Forbes_Asia's_Fab_50_Companies
|
|
gptkbp:CEO
|
gptkb:Vinita_Gupta
|
|
gptkbp:country
|
gptkb:India
|
|
gptkbp:focusArea
|
oncology
pediatrics
women's health
anti-infectives
cardiovascular drugs
respiratory drugs
CNS (central nervous system)
diabetes drugs
gastro-intestinal drugs
|
|
gptkbp:foundedBy
|
gptkb:Desh_Bandhu_Gupta
|
|
gptkbp:foundedYear
|
1968
|
|
gptkbp:hasResearchCenter
|
gptkb:Europe
gptkb:India
gptkb:Japan
gptkb:USA
|
|
gptkbp:headquartersLocation
|
gptkb:Mumbai
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lupin Pharmaceuticals
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
INE326A01037
|
|
gptkbp:listedOn
|
gptkb:NSE
BSE
|
|
gptkbp:Managing_Director
|
gptkb:Nilesh_Gupta
|
|
gptkbp:market
|
gptkb:Africa
gptkb:Asia
gptkb:Australia
gptkb:Europe
gptkb:Japan
gptkb:Latin_America
gptkb:Middle_East
gptkb:Philippines
gptkb:South_Africa
gptkb:United_States
global
|
|
gptkbp:numberOfEmployees
|
over 20,000
|
|
gptkbp:parentCompany
|
gptkb:Lupin_Limited
|
|
gptkbp:products
|
generic drugs
active pharmaceutical ingredients
branded formulations
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:revenue
|
over $2 billion (approximate, varies by year)
|
|
gptkbp:stockExchange
|
gptkb:NSE
BSE
|
|
gptkbp:subsidiary
|
gptkb:Lupin_Pharmaceuticals,_Inc._(USA)
|
|
gptkbp:website
|
https://www.lupin.com/
|
|
gptkbp:bfsParent
|
gptkb:Pimpri-Chinchwad
|
|
gptkbp:bfsLayer
|
6
|